Ginkgo Bioworks Holdings (DNA) Net Cash Flow (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Net Cash Flow of -$23.3 million for Q1 2026, down 141.97% on a QoQ basis from $55.6 million in Q4 2025, and up 90.35% year-over-year from -$12.3 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Net Cash Flow (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$23.3 million for Q1 2026.
- Quarterly Net Cash Flow rose 90.35% year-over-year to -$23.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$175.3 million (up 66.49% YoY) and the FY2025 annual result came in at -$393.6 million, down 2.61% from the prior year.
- Net Cash Flow was -$23.3 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $55.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $55.6 million in Q4 2025 and bottomed at -$241.6 million in Q1 2025.
- A 5-year average of -$82.6 million and a median of -$94.5 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow slumped 557.67% — and 2025, when it soared 199.71%.
- Ginkgo Bioworks Holdings' Net Cash Flow stood at $23.0 million in 2022, then slumped by 557.67% to -$105.1 million in 2023, then surged by 47.0% to -$55.7 million in 2024, then surged by 199.71% to $55.6 million in 2025, then tumbled by 141.97% to -$23.3 million in 2026.
- Business Quant data shows DNA's Net Cash Flow at -$23.3 million in Q1 2026, $55.6 million in Q4 2025, and -$94.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -23.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.32 Mn |
| Mar 31, 2026 | -23.32 Mn |
| Dec 31, 2025 | 55.56 Mn |
| Dec 31, 2025 | 55.56 Mn |
| Sep 30, 2025 | -94.48 Mn |
| Sep 30, 2025 | -94.48 Mn |
| Jun 30, 2025 | -113.01 Mn |
| Jun 30, 2025 | -113.01 Mn |
| Mar 31, 2025 | -241.64 Mn |
| Mar 31, 2025 | -241.64 Mn |
| Dec 31, 2024 | -55.72 Mn |
| Dec 31, 2024 | -55.72 Mn |
| Sep 30, 2024 | -114.17 Mn |
| Sep 30, 2024 | -114.17 Mn |
| Jun 30, 2024 | -111.46 Mn |
| Jun 30, 2024 | -111.46 Mn |
| Mar 31, 2024 | -102.21 Mn |
| Mar 31, 2024 | -102.21 Mn |
| Dec 31, 2023 | -105.14 Mn |
| Dec 31, 2023 | -105.14 Mn |